Giorgio Scagliotti

Giorgio Scagliotti has led landmark clinical trials that defined immunotherapy combinations for non-small cell lung cancer. He conducted the IMpower151 and related trials investigating atezolizumab combinations in NSCLC and has been a central figure in Italian and European lung cancer clinical research. His research contributed to establishing checkpoint inhibitor combinations with chemotherapy as first-line standards for PD-L1-unselected advanced NSCLC. He has investigated biomarkers beyond PD-L1 for predicting immunotherapy benefit in lung cancer including tumor mutational burden and gene expression signatures. His extensive trial leadership across multiple immunotherapy combinations has shaped the current standard-of-care landscape in NSCLC.